pursuing transparency in the life science industry: threat ......report the european transparency...

Post on 01-Aug-2020

6 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Pursuing Transparency in the Life Science

industry: Threat or Business Advantage?

Sabrina Suetens, General Manager

Emeline Blin, Product Manager Compliance

Sabrina.Suetens@cegedim.com

Emeline.blin@cegedim.com

1. The Transparency Agenda

2. Legal, Transversal and Operational Challenges

3. From Pharma 2.0 to Patient Centricity

4. What’s in it for me?

Agenda

The

Transparency

Agenda: A

European &

Belgian

Insight

Report

The European Transparency Agenda

2015 2014 2013

Individual

disclosure begins

EFPIA Transparency

Guidelines

EFPIA Code of

Practice

Data collection by

member companies

Contribution to costs

related to Events

Fees for Service and

Consultancy

Donations

and Grants

Research &

Development

Individual disclosure Aggregate disclosure

Central Platform

HCP (AR78)/ HCO

The Belgian Transparency Agenda

Transfers of Value 2016, Once a year

Visa applications

Transparency

is Legal,

Transversal

and

Operational

challenge

Think Global, Act Local

Self-Regulatory

Legal Provision

EFPIA HCP/HCO DISCLOSURE CODE

Laws vs code of

conduct

Definitions

Data Privacy

Thresholds Industry

involved

Think Global, Act Local

Engagement of HCP

Speaker program / Consulting

Clinical Trials/ Medical Publications

Sponsorships / Donation & Grants

Market Research/ Clinical Trials

Pr J E Smith

UK Hospital

Dr John

Smith Dr Smith Mr J. Smith

Sales &

Marketing

R&D and Medical

Affairs

Corporate

Affairs

Third Party

Vendor/Partners

Unique Identification

Geographies Product Business Unit Customer Vendors

Process Alignment across the Enterprise

From

Pharma 2.0

to Patient

Centricity

Pharma 3.0

Pharma 1.0 Pharma 2.0 Pharma 3.0

Physician Payor

Patient

R&D Productivity

Patent Cliff

Globalization

Demographics

Pricing & Reimbursement

Healthcare Reform

Health IT

Consumerism

Value mining

Business

Model

Customer

Drivers of

change

Patient Centricity

Intent and

Culture

Access and

Pricing

Respecting

patient value

Quality

information

Patient Safety Communications

Transparency

Engagement and

involvement

What’s

in it

for me?

Brand

Awareness

Focus

Commercial

Model on

Product

Marketability

Company

Reputation

+

+

Transform Compliance from Cost to

Competitive Advantage

Patient

centricity

Integrity

Transparency High-quality,

useful products

High-quality

information for

patients

On 800 patient groups from

43 countries and differing

specialties

35.4% (…) stated that multinational

pharma companies had either

an “excellent” or “good”

reputation in 2013, placing

pharma 7th in the

league table of healthcare

industries.*

The Corporate reputation of Pharma

The Patient Perspective

Corporate

Reputation

KPI’s

*Patient View – The Corporate Reputation of Pharma- the Patient Perspective – February 2014

HCP Payment Scrutiny

Advancement of Medical Science

HCP Scientific Contributions

Valuable Industry Relationships

Innovation and Product Development

Public Perception

Media Scrutiny

Aggregate Spend Disclosure Laws

« Meet the high standards of integrity that patients,

governments and other stakeholders expect » EFPIA, June 2013

Identify and analyze customers on which you invest the most.

Analyze spending patterns and identify corresponding customers.

How are your marketing investment allocated?

When do you invest and on which items?

A 360° view of customer’s spend over time.

Leverage your Aggregated Spend solution

into a Business Intelligence Tool

Get an analytics

views of your

promotional

spend.

Reputation knows no national

borders

Conclusion

Turn the transparency

requirements into an essential,

value-generating business

advantage.

Thank You! Sabrina Suetens, General Manager, Cegedim

Emeline Blin, Product Manager Compliance, Cegedim

Sample Management AggregateSpend 360 OneKey

Sabrina.Suetens@cegedim.com

Emeline.blin@cegedim.com

top related